title: Paget's disease of the bone after treatment with Denosumab: a case report.
abstract: Bone affection in Paget's disease is characterized by increased bone turnover localised at one or more sites of the skeleton. Bisphosphonates are the drugs of choice when treating the increased bone turnover in Paget's disease. However, in cases of decreased kidney function only less effective treatments that are available as bisphosphonates are contraindicated in these patients. We present a case of a male patient aged 86 years with GFR of 11 mL/min and Paget's disease successfully treated by Denosumab. The bone turnover and pain decreased upon treatment.
authors.affiliation: Research Center of Ageing and Osteoporosis, Department of Medicine, Glostrup University Hospital, 2600 Glostrup, Denmark. petsch02@glo.regionh.dk
authors.forename: Peter
authors.initials: P
authors.lastname: Schwarz
authors.forename: Anne Qvist
authors.initials: AQ
authors.lastname: Rasmussen
authors.forename: Torben M
authors.initials: TM
authors.lastname: Kvist
authors.forename: Ulrik B
authors.initials: UB
authors.lastname: Andersen
authors.forename: Niklas R
authors.initials: NR
authors.lastname: Jørgensen
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000069448:Denosumab; D006801:Humans; D010001:Osteitis Deformans / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010384:Pelvic Bones / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D011859:Radiography; D011877:Radionuclide Imaging
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069448:Denosumab; D000469:Alkaline Phosphatase